{"id":"nvx-cov2540","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses Novavax's recombinant nanoparticle technology to display stabilized spike proteins from multiple SARS-CoV-2 variants, combined with Matrix-M adjuvant to enhance immune activation. This approach aims to broaden protection against circulating and emerging variants by eliciting both antibody and T-cell responses.","oneSentence":"NVX-CoV2540 is a recombinant protein vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against multiple variants of concern.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:45.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (variant-updated formulation)"}]},"trialDetails":[{"nctId":"NCT05372588","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-05-25","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":1340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omicron BA.5 SARS-CoV-2 rS /Matrix-M Adjuvant"],"phase":"phase_3","status":"active","brandName":"NVX-CoV2540","genericName":"NVX-CoV2540","companyName":"Novavax","companyId":"novavax","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NVX-CoV2540 is a vaccine being studied for its safety and immunogenicity in treating COVID-19 and SARS CoV 2 Infection. It is part of a bivalent vaccine combination, specifically NVX-CoV2373 + NVX-CoV2515, in a Phase 3 boosting study for the SARS-CoV-2 rS variant vaccines.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}